510(k) Report

510(k) · Cleared

Cleared

Clearview Exact PBP2A Test, Model 891-000

K091766510(k) TraditionalCleared Feb 24, 2010252-day reviewClass II21 CFR 866.1640

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Binax, Inc. · MYI System, Test, Genotypic Detection, Resistant Markers, Staphylococcus Colonies

Cleared on Feb 24, 2010 as substantially equivalent to K850291 (Remel Co., 1985) and 1 other predicate after a 252-day review. Its family tree reaches back 1 generation to 1985. 4 later devices descend from it.

Decided
Feb 24, 2010
Review
252 days
Class
Class II
Product code
MYI
Recalls
None
Predicates
2

Its longest line of descent runs back 1 generation to K850291 (1985). 2 ancestors in all. 4 later devices descend from it, 2 citing it directly.

Other ancestors, by year clearedDescendants, by year cleared 2002: 1 other ancestor2012: 1 descendant cleared2017: 1 descendant cleared2019: 1 descendant cleared2025: 1 descendant clearedK850291 · Mueller Hinton Agar W/4% Nacl W/Antibiotics · Remel Co. · 1985 · recalled1990200020102020
Other ancestors, by generationDescendants, by generation 1 generation back: 1 other ancestor 1 generation forward: 2 descendants2 generations forward: 1 descendant3 generations forward: 1 descendant K850291 · Mueller Hinton Agar W/4% Nacl W/Antibiotics · Remel Co. · 1985 · recalled0
  1. Root · 1 generation backK850291 Mueller Hinton Agar W/4% Nacl W/AntibioticsRemel Co. · 1985 · Recalled
  2. This deviceK091766 Clearview Exact PBP2A Test, Model 891-000Binax, Inc. · 2010
  3. Descendant · cites it directly · 2 of its ownK162385 Rapidec Carba NPBiomerieux S.A. · 2017
  4. Descendant · 2 generations on · 1 of its ownK191889 NG-Test CARBA 5Ng Biotech · 2019
  5. Descendant · 3 generations on · 0 of its ownK243499 NG-Test® CTX-M MULTINg Biotech · 2025
  6. Descendant · cites it directly · 0 of its ownK121905 Alere PBP2A TestAlere Scarborough, Inc. · 2012

Most influential descendants

Showing 4 of 4 · See all
  • K162385Rapidec Carba NPBiomerieux S.A. · 2017 · cites it directly2descendants
  • K191889NG-Test CARBA 5Ng Biotech · 2019 · 2 generations on1descendant
  • K243499NG-Test® CTX-M MULTINg Biotech · 2025 · 3 generations on0descendants
  • K121905Alere PBP2A TestAlere Scarborough, Inc. · 2012 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K850291Mueller Hinton Agar W/4% Nacl W/AntibioticsRemel Co.19852
0 (this device)K091766Clearview Exact PBP2A Test, Model 891-000Binax, Inc.2010—
+1K162385Rapidec Carba NPBiomerieux S.A.2017—
+2K191889NG-Test CARBA 5Ng Biotech2019—
+3K243499NG-Test® CTX-M MULTINg Biotech2025—
+1K121905Alere PBP2A TestAlere Scarborough, Inc.2012—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
200210

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201210
201710
201910
202510
FIG. 1 — Lineage of K091766, 1985–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MYI? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K850291Mueller Hinton Agar W/4% Nacl W/Antibiotics
Summary page 1
…Test, Genotypic Detection, Resistant Markers, Staphylococcus Colonies (MYI) (per 21 CFR 866.1640) PREDICATE DEVICES Mueller Hinton Agar w/4% NaCI w/Antibiotics (Remel) K850291 PBP2' Latex Agglutination Test (Oxoid) K01 171 0 DEVICE DESCRIPTION The Clearview® Exact PBP2a Test is a rapid immunochromatogra…
Remel Co.19852
*K011710Oxoid PBP2 1 Latex Agglutination Test
Summary page 1
…Staphylococcus Colonies (MYI) (per 21 CFR 866.1640) PREDICATE DEVICES Mueller Hinton Agar w/4% NaCI w/Antibiotics (Remel) K850291 PBP2' Latex Agglutination Test (Oxoid) K01 171 0 DEVICE DESCRIPTION The Clearview® Exact PBP2a Test is a rapid immunochromatographic membrane assay that uses highly sensitive mo…
Oxoid, Ltd.2002—

Also cleared against K850291: 2 other devices →

What descends from it? (4)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K162385Rapidec Carba NPBiomerieux S.A.20172
K121905Alere PBP2A TestAlere Scarborough, Inc.20120

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • 1 of the 2 ancestors has a recall of any class.
  • Of its descendants, K162385 (Biomerieux S.A., 2017) has gone furthest, with 2 descendants of its own.
  • 2 other devices also cite its predicate K850291.

How does its category compare?

All MYI devices

MYI System, Test, Genotypic Detection, Resistant Markers, Staphylococcus Colonies: FDA decisions, review times, recalls and adverse event reports over 20 years. 2010, this device’s year, is highlighted.

FDA decisions per year · MYI

2in 2014

2010: 22012: 12014: 2
2007high 2 (2010) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MYI

Too few MYI 510(k)s in any year since 2007 to give a median.

Recalls per year · MYI

No recall names MYI since 2007.

Adverse event reports per year · MYI

2in 2023

2023: 2
2007high 2 (2023) · low 0 (2007)2025

MAUDE reports naming product code MYI, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20102—00
20110—00
20121—00
20130—00
20142—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20230—02
20240—00
20250—00
20260—0—

What is it indicated for?

The Clearview® Exact PBP2a Test is a qualitative, in vitro immunochromatographic assay for the detection of penicillin-binding protein 2a (FBP2a) in isolates identified as Staphylococcus aureus, as an aid in detecting methicillin-resistant Staphylococcus aureus (MRA) The Clearview® Exact PBP2a Test is not intended to diagnose MRSA nor to guide or monitor treatment for MRSA infections.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K091766: Clearview Exact PBP2A Test, Model 891-000.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K091766

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026